Best Sellers

Cagrilintide is an experimental long-acting amylin analogue developed to mimic the biological activity of the naturally occurring hormone amylin, which is co-secreted with insulin by pancreatic beta cells. Researchers have investigated Cagrilintide for its potential effects on appetite regulation, gastric emptying, and metabolic homeostasis.

In laboratory and preclinical studies, Cagrilintide has demonstrated prolonged receptor activity due to structural modifications designed to enhance its stability and duration of action. Scientific interest in this peptide has focused on its ability to influence satiety signaling pathways and energy balance mechanisms.

Ongoing research continues to explore its pharmacological properties, receptor interactions, and potential applications in metabolic science. However, Cagrilintide remains under scientific investigation, and additional studies are required to further evaluate its biological activity, safety profile, and long-term effects.

Cagrilintide is intended strictly for research purposes and has not been approved for use outside of authorized clinical and scientific settings.

Cartalax (AED Peptide) is an experimental tripeptide composed of the amino acid sequence Ala-Glu-Asp (AED), currently being studied for its potential role in cellular regulation and connective tissue maintenance. Research suggests that peptides in this class may influence biological pathways associated with tissue homeostasis, cellular communication, and age-related physiological processes.

In laboratory settings, Cartalax is primarily used to investigate its molecular activity, tissue-specific effects, and potential interactions with cellular repair mechanisms. Ongoing studies continue to explore its biological properties and possible applications in regenerative and longevity-related research.

Cartalax is intended strictly for research purposes and has not been approved for clinical use in humans. Further studies are required to fully understand its safety, efficacy, and mechanism of action.

GLP-3 RT (Glucagon-Like Peptide-3, Research Type) is an experimental peptide from the glucagon-like peptide family, currently studied for its potential role in metabolic and neuroendocrine regulation. Structurally related to incretin peptides, it is being investigated in research settings for its possible effects on glucose homeostasis, appetite control, and central nervous system signaling, including pathways associated with insulin secretion and energy balance. Preliminary findings suggest it may influence metabolic responses and satiety-related mechanisms; however, GLP-3 RT remains in early-stage investigation and is not approved for human use, being strictly limited to laboratory research while further studies are required to establish its safety, efficacy, and pharmacological profile.